The question
Oral semaglutide works as a carefully developed formulation. Its absorption cannot be inferred simply from the presence of semaglutide in a capsule, liquid or research vial. The tablet combines the peptide with an absorption enhancer called SNAC; the formulation and the conditions under which it was studied are part of the evidence.
This distinction resolves an apparent puzzle. A peptide can be difficult to deliver by mouth while a particular oral medicine containing that peptide can still work. “Difficult to deliver” is an engineering problem to investigate, not proof that all oral peptides fail or that any swallowed version will succeed.
Getting into blood is a separate research question
Early mechanistic research combined clinical observations with preclinical experiments, including dogs. It found absorption concentrated in the stomach near the tablet and dependent on coformulation with SNAC. The authors described a compound-specific mechanism rather than a universal route for all peptides. Original absorption research.
The distinction between preclinical and human evidence matters here. A laboratory or animal experiment can help explain how a formulation might cross a barrier. It cannot, by itself, establish the treatment benefit of a commercial oral product in people. That requires evidence for the finished formulation and the clinical outcome being claimed.
Pharmacokinetics is the study of a drug's concentration over time. A blood-concentration curve can answer whether and how much drug reaches circulation under test conditions. It is a different kind of evidence from a trial asking whether people experience fewer clinical events or better disease control. Both can be valuable without being interchangeable.
The food experiment made the delivery problem visible
A published food-effect trial randomized 78 healthy participants and studied oral semaglutide over ten days. In the fed group, 14 of 25 evaluable participants had no measurable semaglutide exposure; the other 11 had limited exposure. All participants in the fasting group had measurable exposure. A separate dosing-conditions trial randomized 161 healthy men and examined water volumes and post-dose fasting periods. The work was funded by Novo Nordisk. Primary pharmacokinetic studies.
Those observations make the formulation story concrete. The same named molecule did not produce the same exposure under every condition. However, “no measurable exposure” describes the assay result under that protocol; it should not be rewritten as a universal statement that no molecule could ever have crossed the stomach wall.
The studies were short and involved healthy volunteers, with the second trial limited to men. They were designed around pharmacokinetic questions, not long-term weight loss or prevention of complications. A chart of drug exposure is not a substitute for those outcomes. It is also not a reason to experiment with fasting or tablet manipulation to chase a larger concentration: the current product instructions and the prescriber's advice remain the reference for use.
Low bioavailability does not mean no effect
The US label reviewed on October 5, 2026 lists estimated absolute bioavailability of approximately 0.4–1% for Rybelsus tablets and 1–2% for Ozempic tablets. Both are oral semaglutide formulations, but the label says they are not substitutable milligram for milligram. It describes absorption as predominantly gastric. Current oral semaglutide labeling, section 12.3.
Bioavailability is not a patient success rate. A figure of 1% does not mean that one person in a hundred benefits, or that the treatment has “1% of the effectiveness” of an injection. It concerns the fraction of an administered amount that reaches systemic circulation. Clinical effectiveness is assessed through clinical studies of the actual formulation.
The reverse shortcut is also misleading: a higher absorption estimate does not automatically make one product clinically better for a given person. Dose, exposure over time, the tested indication, tolerability and individual circumstances are separate considerations. The label's formulation-specific comparison is a good reason to avoid doing a homemade milligram conversion.
Product names and routes need to travel together
The current US labeling covers Rybelsus and Ozempic tablets for adults with type 2 diabetes, including specified glucose-control and cardiovascular-risk indications. Older explanations that use “Ozempic” as shorthand for an injection can therefore leave out relevant formulation detail. Read the full product name and route rather than relying on the brand alone. US label, indications and formulation information.
This article is about delivery science, not a complete inventory of every semaglutide product. Its practical reading test is simple: does a claim identify the exact formulation studied? If a seller cites a trial of an approved tablet to support a different liquid, capsule or research material, the missing evidence is the connection between those products. A shared ingredient name does not supply that connection.
The same discipline applies when reading our semaglutide kidney-trial explainer: outcome evidence belongs to the study's population and formulation. Our compounded semaglutide guide addresses another common source of product confusion.
Oral delivery is an achievement worth understanding precisely. It shows why the surrounding formulation deserves attention alongside the peptide name, and why an appealing claim about “oral peptides” still needs product-specific evidence.
Sources & further reading
Research context last reviewed October 5, 2026. Last updated October 5, 2026. Educational reading, not individual medical advice. How this article was prepared.
